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Summary 
Microglia of the developing brain have unique functional properties but how their activation states is 
regulated is poorly understood. Inflammatory activation of microglia in the still-developing brain of 
preterm born infants is associated with permanent neurological sequelae in 9 million infants every 
year. Investigating the regulators of microglial activation in the developing brain with multiple models 
of neuroinflammation-mediated injury and primary human microglia we found that a reduction in 
Wnt/β-catenin signalling is necessary and sufficient to drive an oligodendrocyte-injurious microglial 
phenotype. We validated in a cohort of preterm born infants that genomic variation in the WNT 
pathway is associated with the levels of connectivity found in their brains. Using a Wnt agonist 
delivered by a BBB penetrant microglia-specific targeting nanocarrier we prevented in our animal 
model the pro-inflammatory microglial activation, white matter injury and behavioural deficits. 
Collectively, these data validate that the Wnt pathway regulates microglial activation, is critical in the 
evolution of an important form of human brain injury and is a viable therapeutic target.  
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Introduction 
 Neuroinflammation is a key pathological mechanism in almost all acute and degenerative 
diseases in both the adult and in the developing brain(Hagberg et al 2012, Perry et al 2010, Prinz et 
al 2011). Microglia (MG) and infiltrating macrophages (Mφ) are major contributors to 
neuroinflammation(Perry et al 2010). These cells are capable of acquiring numerous complex 
functional states dependent on the specific nature of an insult or injury, including cytotoxic 
responses, immune regulation, or injury resolution(Wolf et al 2017). Limiting the cytotoxic activation 
of MG/Mφ while promoting injury resolution represents a rational neuroprotective strategy(Miron et al 
2013, Rivest 2009), that requires an in-depth understanding of the molecular mechanisms controlling 
their phenotypes across forms of injury. Understanding of these regulatory mechanisms is increasing 
at an extraordinary rate for adult disorders. However, recent work has shown that MG do not reach 
maturity until around the time of birth in humans, or the equivalent developmental time point of 
approximately postnatal day 14 in rodents(Bennett et al 2016, Butovsky et al 2014, Krasemann et al 
2017, Miyamoto et al 2016). These MG have specialised functions in brain development, such as 
synaptic pruning(Delpech et al 2016, Paolicelli et al 2011), but there is a striking paucity of 
knowledge on the regulators of MG phenotype in that is relevant to injury/insult to the developing 
brain.  
Preterm birth is the commonest cause of death and disability in children under 5 years of age, 
exceeding deaths from malaria or pneumonia(Lim et al 2012). Preterm birth, birth before 37 of 40 
weeks’ gestation, occurs in fifteen million infants yearly, rates are increasing in developed countries 
(e.g. 7% of all births in the UK; 13% in the US) and we are limited in our predictive and therapeutic 
options for these vulnerable infants. Up to 60% of infants born preterm we be left with persistent 
cognitive and neuropsychiatric deficits including autism-spectrum, attention-deficit disorders and 
epilepsy(Delobel-Ayoub et al 2009, Wood et al 2000). Insights into the previously poorly understood 
pathophysiology of preterm birth(Back et al 2005, Billiards et al 2008, Delobel-Ayoub et al 2009, 
Moore et al 2012, Verney et al 2012) have enabled us to design animal models of improved 
relevance to the constellation of injuries seen in contemporary cohort of infants, collectively called 
encephalopathy of the premature infant: MG/Mφ activation, oligodendrocyte maturation blockade, 
myelin deficits and axonapathy. MG/Mφ activation driving neuroinflammation in preterm born infants 
is often caused by exposure to maternal fetal infections or inflammation, such as chorioamnionitis, or 
post-natal sepsis. The endemic but often clinically silent maternal inflammatory events are 
considered the chief cause of preterm birth(Wu et al 2009) and exposure to inflammation is the 
strongest predictor of poor neurological outcome(Dammann & Leviton 2004, Hillier et al 1993, Wu et 
al 2009).  
The Wnt (i.e. wingless-type MMTV [mouse mammary tumour virus] integration site) pathways 
have well studied critical roles in the early developmental events of body axis patterning, and brain 
cell fate specification, proliferation and migration(Sokol 2015). Wnt signalling is divided into the 
canonical Wnt/β-catenin and non-canonical Wnt/planar cell polarity (PCP) and Wnt/calcium 
pathways. Aberrant regulation of canonical WNT/β-catenin signalling is strongly implicated in the 
onset and progression of numerous cancers(Zhan et al 2017). The effects of Wnt pathway activation 
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are highly cell and context specific and any key regulatory role of the Wnt pathways in the response 
of MG/Mφ to injury or insult has not been demonstrated, especially in the developing brain. Although, 
activation of the Frizzled receptors (a family of G protein-coupled receptors) with Wnt ligands has 
complex effects on some facets of MG activity in vitro(Halleskog et al 2012, Halleskog & Schulte 
2013). Experimental evidence in other cell types also supports that the Wnt/ β-catenin pathway is 
involved in aspects of inflammatory signalling, namely there are links between expression of the 
inflammatory mediator COX2 (cyclooxygenase-2) and Wnt/β-catenin in cancer(Buchanan & DuBois 
2006), and that β-catenin regulates at numerous levels the cytokine/pathogen induced activation of 
NF-κB (Ma & Hottiger 2016). As such, in the hunt for a regulator of immature MG activation state with 
a view to therapy design the Wnt pathway is an interesting and rationale candidate. 
In the present study, we used our model of encephalopathy of prematurity and we have 
clearly demonstrated a causal link between MG/Mφ activation and oligodendrocyte injury/myelin 
deficit. Using a combination of approaches across species, including human, we reveal for the first 
time that inhibition of the Wnt/β-catenin pathway is necessary and sufficient to drive this MG/Mφ pro-
inflammatory phenotypic transformation. We also verified the clinical relevance of the Wnt pathway to 
anatomical white matter structure in a cohort of human preterm born infant brain using an integrated 
imaging genomics analysis. Finally, we employed a novel 3DNA nanocarrier that carries cargo 
across the blood brain barrier (BBB) following non-invasive intraperitoneal (i.p.) administration and 
that then delivers cargo specifically to MG/Mφ. Using this 3DNA nanocarrier we show that preventing 
Wnt pathway down-regulation specifically in MG/Mφ reduces the pro-inflammatory MG/Mφ 
phenotype, white matter damage and long-term memory deficit in our model of encephalopathy of 
prematurity.  
Altogether, these findings identify the Wnt/β-catenin pathway as a key regulator of MG/Mφ 
activation state across species and a potential target for the treatment of encephalopathy of 
prematurity and other neuroinflammatory conditions.   
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Results 
MG activation drives hypomyelination in our model of encephalopathy of the premature infant 
To understand the mechanisms underpinning encephalopathy of the premature infant in 
contemporaneous cohorts we previously set up a model mimicking its neuropathological, behavioural 
and imaging phenotypes(Favrais et al 2011, Krishnan et al 2017). Of note, the neuropathological 
similarities between our model and clinical studies includes MG/Mφ activation and hypomyelination 
due to the maturation blockade of oligodendrocytes but not cell death(Billiards et al 2008, Verney et 
al 2010, Verney et al 2012). Specifically, intraperitoneal (i.p.) injections of interleukin (IL)-1β 
(10μg/kg) were administered to mouse pups twice daily on postnatal days (P) 1-4 and once at P5 
(Figure 1a). P1-P5 in the mouse is a developmental period roughly corresponding to 22-32 weeks of 
human pregnancy(Marret et al 1995) and this is the greatest period of vulnerability for white matter 
damage in preterm born infants. Exposure to systemic IL-1β recapitulates the systemic inflammatory 
insult of maternal/fetal infections, such as chorioamnionitis, that are responsible for setting up 
neuroinflammation via the activation of endothelial cell IL-1 receptors. In our model, we verified a 
direct causal link between MG/Mφ activation and neuropathology by selectively killing pro-
inflammatory MG/Mφ and observing a reduction in myelin injury. Specifically, we used a intracerebral 
injection of gadolinium chloride (GdCl3), which kills pro-inflammatory MG/Mφ via competitive 
inhibition of calcium mobilization and damage to the plasma membrane, as previously validated in 
vivo (Du et al 2014, Fulci et al 2007, Miron et al 2013). This approach was chosen as ablation of MG 
with a Tamoxifen driven transgenic or other pharmacologic approaches (i.e. PLX3397, ganciclovir) is 
not feasible as our studies target maturing oligodendrocytes (as found in the preterm infant brain) 
that are present from P1. Also, embryonic depletion itself alters brain development(Squarzoni et al 
2014). GdCl3 (200nmol) was injected into the corpus callosum of P1 mice prior to i.p injection of IL-1β 
or PBS. In the corpus callosum, 3 hours after the first IL-1β injection (at P1), immunohistological 
analysis revealed that the majority of MG/Mφ were IBA1+/COX2+ and the numbers of these cells 
was reduced by approximately 50% by GdCl3 (Figure 1b,c). This GdCl3-mediated reduction in 
MG/Mφ prevented the typical loss of myelin basic protein (MBP) in the corpus callosum at P30 
(Figure 1d,e). A link between microglial activation and oligodendrocyte injury can also be 
recapitulated with IL-1β exposure of mixed glial cultures containing oligodendrocyte progenitor cells 
(OPCs), MG and astrocytes. In these in vitro conditions, there in reduced MBP+ cell density, without 
affecting the total number of oligodendrocytes (Figure 1f). Exposure of pure OPC cultures to IL-1β in 
the absence of microglia or astrocytes did cause hypomyelination (data not shown). Altogether, these 
results validate in our model a causal link between MG/Mφ activation and the hypomyelination that is 
a hallmark of encephalopathy of prematurity. 
 
MG activation is persistent with specific temporal patterns in our model of encephalopathy of the 
preterm infant 
We comprehensively characterized the morphology, gene and protein expression of MG/Mφ 
over time in our model to assess the relationship between activation states and injury. Our 
morphological analysis of GFP+ MG/Mφ from CX3CR1GFP/+ mice revealed a moderate but significant 
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/334359doi: bioRxiv preprint first posted online May. 31, 2018; 
 6
reduction of complexity (arborisation) at P3 when comparing MG/Mφ from IL-1β versus PBS injected 
animals but no difference in process length or density, cell body area, numbers of primary, secondary 
and tertiary processes, or the area covered by the MG processes in 2D (Figure 2a,b). Cell 
morphology was measured at 3 hours after the first inflammatory challenge (at P1) and at P3 when 
animals had been exposed to >48 hours of systemic inflammation driven neuroinflammation in 
vibratome cut sections using a custom designed script developed with the Acapella™ image 
analysis(Verdonk et al 2016).  
We further studied MG/Mφ activation using expression analysis of sixteen genes and six 
protein markers previously associated with polarized expression states(Chhor et al 2013, Miron et al 
2013) at 5 time points. Gene expression analysis was performed in CD11B+ cells isolated by 
magnetically activated cell sorting (MACS, Miltenyi Biotec) from PBS- or IL-1β-exposed mice as per 
our previous studies(Chhor et al 2017, Krishnan et al 2017, Shiow et al 2017). Prior FACS analysis 
has demonstrated that the ratio of MG to other CD11B+ cells in this isolate is greater than 50 to 
1(Krishnan et al 2017). Nevertheless, because we cannot exclude the presence of Mφ completely we 
use MG/Mφ as the descriptor for these cell isolates. Also, the purity of the MACS isolation was 
confirmed as >95% CD11B+ MG/Mφ by FACS and qRT-PCR, also as previously(Krishnan et al 
2017, Schang et al 2014). qRT-PCR based gene expression analysis (Figure 2c) and 
immunofluorescence (Supp Figure 1a-d) showed that systemic exposure to IL-1β induced a robust 
pro-inflammatory MG/Mφ activation state at P1, only 3 hours following the first injection of IL-1β. 
Specifically, 5/6 markers of a pro-inflammatory state were significantly increased including Il6 
increased by 20-fold, and a 5-fold increases in Ptgs2 and Nos2, all p<0.001. Of note, Ptgs2 and 
Nos2 remained elevated for 5 days, but Il6 and Tnfa were returned to normal by P3. There was a 
similar robust increase in markers of immune-regulation at P1 as 4/4 markers were increased 
including an 8-fold increase in Socs3 and >10-fold increase for Sphk1 and Il1rn, all p<0.001. 
Expression of markers associated with an anti-inflammatory activation state were the most effected 
in animals exposed to systemic IL-1β exposure at P2 and P3, which is 48 or 72 hours after the start 
of IL-1β injections. These findings of a temporal change in MG/Mφ activation profiles were 
corroborated with immunohistological analysis of protein levels (Supp Figure 1a-d).   
By combining our observations of morphology, gene and protein changes in MG/Mφ after 
systemic IL-1β exposure we have characterized a persistent state of activation responsible for injury 
to the developing white matter.  
 
The Wnt pathway is comprehensively down-regulated in activated MG in vivo and in vitro 
 In mouse pups exposed to systemic IL-1β we have characterized a persistent activation of 
MG between P1 and until at least P5, which induces a partial blockade of OPC maturation and 
subsequently hypomyelination(Favrais et al 2011). Using gene and predicted protein network-based 
analysis, we sought to identify molecular pathways regulating this MG/Mφ activation driving OPC 
injury. We hypothesized that the best time to pick-up the potential disrupting regulator pathways 
specific to developing MG was P5 when MG are activated and when the first effects of OPCs have 
been observed and P10 when MG activation is apparently resolved but injury to OPCs is well 
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established. As such, we undertook genome-wide transcriptomics analysis of MG/Mφ (CD11B+) and 
OPCs (O4+) MACSed at P5 and P10 from the brains of mice exposed to IL-1β or PBS. The purity of 
the O4+ MACS isolation was verified with qPCR(Schang et al 2014) as outlined for CD11B fractions 
above. Genes showing differential expression between time points, P5 and P10, were identified for 
each cell-type, MG/Mφ (CD11B+) or OPCs (O4+), within each condition, IL-1β or PBS. Gene co-
expression networks were inferred for each of the four sets of differentially expressed genes using 
Graphical Gaussian Models (GGMs)(Opgen-Rhein & Strimmer 2007). GGMs use partial correlations 
to infer significant co-expression relationships. We applied a False Discovery Rate (FDR) of <1% 
between any microarray probe pair in each of the four sets of differentially expressed genes sets 
previously identified: PBS-OPC, IL-1β-OPC, PBS-MG/Mφ and IL-1β-MG/Mφ. These four co-
expression networks were found to exhibit unique topologies and functional annotations (Supp 
Figure 2a,b; Supp Tables 1 and 2). Compared to the three other conditions networks, the IL-1β 
exposed MG/Mφ co-expression network was the most highly interconnected and the densest 
indicating a strong co-regulation of gene expression under this condition (Supp Figure 2a,b). 
Biological pathway analysis using the Broad Institute MsigDB database(Subramanian et al 2005) 
indicated enrichment for Wnt signalling pathway genes within the IL-1β exposed MG/Mφ network 
(FDR=8.5 x 10-7; Figure 3a; Supp Table 2). Due to the proposed importance of the Wnt pathway in 
OPC maturation(Fancy et al 2009) we undertook a specific analysis of data from the O4+ OPCs from 
mice subjected to systemic exposure to IL-1β. Analysis of microarray data from the O4+ OPCs did 
not show any significant enrichment for Wnt signalling genes in the gene co-expression response 
(Supp Table 2). This data highlight two important facts about Wnt dysregulation, firstly, that Wnt 
dysregulation is likely not a mechanism of oligodendrocyte maturation arrest in this model, and 
second, that changes in Wnt are not simply ubiquitous in the developing CNS in response to 
inflammation. Returning to the analysis of MG/Mφ, to highlight the directionality of the data, 
enrichments for Wnt signalling pathway sets were specifically noted among the genes significantly 
down-regulated by IL-1β exposure at P5 and P10 (Supp Table 3, see Methods). The known 
interactions among the Wnt pathway genes plus predicted interactors were then retrieved from an 
extensive set of functional association data by the GeneMania tool (Warde-Farley et al 2010) and we 
represented this sub-network (Figure 3b). We have also annotated this figure to highlight that the 
vast majority of targets predicted to interact in this model have down-regulated expression. Finally, 
qualitative gene profiling with qRT-PCR in CD11B+ MG/Mφ confirmed the down-regulation of mRNA 
expression for numerous Wnt pathway members including multiple Fzd receptors, Lef1 and Ctnnb1 
in MG/Mφ from IL-1β-exposed mice (Figure 3c). The down-regulation of Ctnnb1 mRNA was also 
accompanied by a significant decrease in the expression of β-catenin protein in CD11B+ MG/Mφ at 
P3 corresponding to the time point when the greatest morphological changes and pro-inflammatory 
gene activation is observed (Figure 3d). 
 To extend this ex vivo CD11B+ cell data and set up an in vitro model for further study, qRT-
PCR and immunofluorescence analysis of mouse primary cultured MG was undertaken. The cultures 
are >97% pure for MG as validated with IHC and qRT-PCR, as previously(Chhor et al 2013). 
Exposure of MG to IL-1β in vitro induces a similar pro-inflammatory phenotype as is found in MG/Mφ 
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from mice exposed to systemic IL-1β (Supp Figure 3a,b). Furthermore, we observed a similar down-
regulation of Wnt pathway members including mRNA encoding Fzd receptors, Ctnnb1 and Tcf1 
(Supp Figure 3c). Inducing a pro-inflammatory activation in MG in vitro also induced an upregulation 
of mRNA encoding Axin1 and Axin2, two specific inhibitors of β-catenin nuclear translocation (Supp 
Figure 3c) and reduced the protein levels for β-catenin as assessed with immunofluorescence 
(Supp Figure 3d), and ELISA (Supp Figure 3e). There was no significant change in the ratio of 
phosphorylated (Pser45) β-catenin to β-catenin (Supp Figure 3e). In contrast, IL-4, a classic anti-
inflammatory stimulus, increased Wnt/β-catenin activation as indicated by strongly increased Lef1 
mRNA and decreased the Pser45 β-catenin/β-catenin ratio measured via ELISA (Supp Figure 3f,g).  
Altogether these data demonstrate that a pro-inflammatory MG/Mφ phenotype is associated 
with a robust and comprehensive down-regulation of the gene and protein expression of members of 
the Wnt/β-catenin signalling pathway in vivo and in vitro. 
 
Wnt/β-catenin pathway activity negatively correlates with pro-inflammatory MG activation in vitro 
 We next sought to determine if Wnt/β-catenin pathway modulation alone is sufficient to drive 
phenotypic changes in MG in vitro. Pharmacological inhibition of the Wnt/β-catenin pathway in vitro 
with XAV939, a tankyrase inhibitor that stabilizes the Wnt/β-catenin pathway inhibitor Axin2 (Fancy et 
al 2011), was sufficient to promote a pro-inflammatory phenotype, mimicking the effects of IL-1β 
(Figure 3e). Conversely, the IL-1β-induced pro-inflammatory MG phenotype was blocked by 
activating the Wnt pathway using siRNAs against Axin2 (Figure 3f; validation of siRNA efficacy 
Supp Fig 3h) or a pharmacological inhibitor of GSK3β that phosphorylates and inactivates β-catenin, 
CT99021(Ring et al 2003) (Figure 3g). As expected, we verified with ELISA that the Pser45 β-
catenin/β-catenin ratio was increased with XAV939, and decreased with Axin2 siRNA and CT99021 
(Figure 3h). In contrast, we tested in PBS and IL-1β-exposed primary MG a non-isoform specific 
block of PKC signalling with Chelerythrine. Chelerythrine targets the non-canonical Wnt pathways 
and exposure of doses from 1-3µM had no effect on MG activation (Supp Figure 4). 
Altogether, these data verify in pure cultures of primary MG that that modulating the Wnt/β-
catenin pathway is sufficient and necessary to effect MG activation state. 
 
Wnt/β-catenin pathway activity negatively correlates with pro-inflammatory MG activation in vivo 
 We further tested our working hypothesis that Wnt/β-catenin signalling drives a pro-
inflammatory phenotype in MG/Mφ in vivo using non-cell specific approaches in zebrafish and mice 
and then transgenic mice with MG/Mφ specific β-catenin knock-down. In zebrafish larvae at 72 hours’ 
post-fertilization (hpf) that express RFP in MG/Mφ (Tg[pU1::Gal4-UAS-TagRFP]) we injected into the 
hindbrain the prototypical pro-inflammatory agent lipopolysaccharide (LPS) (Figure 4a). LPS was 
used due to the unavailability of recombinant zebrafish IL-1β and prior work demonstrating the 
expression by zebrafish of receptors for LPS, the Toll-like 4 receptor (TLR4), and the requisite 
downstream signalling cascade(van der Sar et al 2006). LPS-induced neuroinflammation was 
confirmed after 48 hours by a significant increase in fluorescent MG/Mφ in the optic tectum (Figure 
4b,c). We observe a similar increase in MG/Mφ immunofluorescence in our mouse model with IBA1 
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and MAC1 immunofluorescence(Favrais et al 2011). As expected, exposure of zebrafish larvae to 
the Wnt/β-catenin antagonist XAV939 exacerbated the LPS-induced MG/Mφ activation, while 
conversely exposure to Wnt agonists acting via the canonical GSK3β dependent pathway with 
CT99021 or LiCl prevented the LPS induced MG/Mφ activation (Figure 4b,c).  
Subsequently, we studied the specific relationship between Wnt/β-catenin pathway activity 
and MG/Mφ activation in mice using pharmacological and genetic approaches. Firstly, we inhibited 
the Wnt/β-catenin pathway by intracerebroventricular (i.c.v.) injection of XAV939 in P1 pups and 
isolated CD11B+ MG/Mφ 3 hours later.  In agreement with our hypothesis, in vivo Wnt inhibition with 
XAV939 mimicked the effects of systemic IL-1β on gene expression in MG/Mφ (Figure 4d). 
Furthermore, to specifically target the Wnt pathway in MG/Mφ, we bred LysMCre/Cre with β-
cateninFlox/Flox mice to generate β-Cat∆/+ transgenic mice. Recombination, and as such KO, of β-
catenin occurs in ≥20% of MG/Mφ in this Cre line(Cho et al 2008, Degos et al 2013, Derecki et al 
2012). In the absence of external inflammatory stimuli, β-Cat∆/+ mice with MG expressing reduced 
levels of β-catenin developed a myelin deficiency that mimicked the damaging effects of systemic IL-
1β exposure in our encephalopathy of prematurity model. Specifically, these mice had reduced Mbp 
mRNA in the anterior cortex at P10 (Figure 4e) and reduced MBP immunoreactivity in the corpus 
callosum and cingulum at P30 (Figure 4f,g).  
Collectively, these data show that in an invertebrate and a vertebrate species that down-
regulation of the Wnt pathway is sufficient and necessary to drive a pro-inflammatory MG/Mφ 
activation state. Of note, even a partial MG/Mφ-specific β-catenin deletion in vivo in the absence of 
any external stimuli is sufficient to induce MG/Mφ activation leading to a myelination defect.  
 
The Wnt pathway regulates activation state in primary human MG in vitro 
We then verified a similar relationship between decreased Wnt and increased pro-
inflammatory activation in primary human MACSed CD11B+ MG/Mφ isolated from cerebral tissues 
collected from scheduled terminations at 19 and 20 weeks’ gestational age. Based on the scarcity 
and value of these cells we chose to use LPS to induce a pro-inflammatory MG response based on 
previous studies(Melief et al 2012). Human primary MG/Mφ were activated to a pro-inflammatory 
state as indicated by modified morphology (Figure 5a) and increased COX2 gene expression 
(PTGS2 mRNA) (Figure 5b). In agreement with what we observed in our mouse and zebrafish 
experiments these pro-inflammatory activated human primary MG had a reduction in their expression 
of mRNA for the β-catenin gene, CTNNB1 (Figure 5c). 
 
Genomic variance in WNT pathway genes is relevant to human preterm infant white matter structure  
Our experimental data show that genetic knockdown of Wnt/β-catenin signalling is sufficient 
itself to drive brain injury in transgenic mice. In a conceptually similar manner, but with an expected 
much smaller effect size, we reasoned that that genetic variation in WNT pathway genes would be 
associated with surrogates of white matter mediated connectivity in preterm born infants. We 
hypothesize that, at least in part, any link between WNT variation and connectivity would be 
mediated by differences in the innate response to inflammatory challenge in these preterm infants. 
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Although our genetic analysis is agnostic with respect to cellular mechanism or type, a link between 
WNT variations and brain structure would support further research into WNTs role in injury, and 
using WNT variants for preterm born infant injury/outcome stratification. To test our prediction of a 
link between WNT and preterm brain connectivity we performed an analysis where we jointly 
analysed imaging data and genomics data from 290 preterm born infants. This approach has 
previously uncovered novel genetic variants associated with brain connectivity phenotype (Krishnan 
et al 2017, Krishnan et al 2016). Specifically, we assessed single nucleotide polymorphisms (SNPs), 
DNA sequence variations where a single nucleotide varies between individual members of a species 
that can help pinpoint contributions of specific genes to disease states. 
To define the intra-cerebral anatomical connectivity phenotype in our preterm cohort, we used 
3-T dMRI and optimized probabilistic tractography as previously described(Robinson et al 2008, Shi 
et al 2011), adjusting the results for post-menstrual age at scan and at birth. Regions of interest for 
seeding tractography were obtained by segmentation of the brain based on a 90-node anatomical 
neonatal atlas(Shi et al 2011), focusing on cortico-cortical connections. DNA extracted from saliva 
was genotyped and a gene-set-of-interest defined using SNPs in the WNT signalling pathway (entry 
hsa04310) of the Kyoto Encyclopaedia of Genes and Genomes (KEGG) (n=141 genes).  
SNPs were mapped to all of the genes in the KEGG WNT pathway using the JAG tool and 
Genome Reference Consortium Human Build 37 (GRCh37; hg19), using 2kb up/downstream, in line 
with NCBI practices (NCBI 2005). Following SNP-gene mapping, we tested the null hypothesis that 
variation in WNT pathway genes is not associated with the preterm tractography phenotype using 
Joint Association of Genetic Variants (JAG)(Lips et al 2015). Specifically, genes in the WNT-set were 
tested in two ways (Figure 5d). Firstly, we performed a “competitive/enrichment test” to determine 
whether the WNT pathway genes were no more associated with the connectivity phenotype than 300 
randomly drawn non-WNT-pathway gene-sets. Secondly, we performed a “self-contained/association 
test” to determine whether there is a comparable association between the original connectivity 
phenotype and WNT, versus 1000 random permutations of the phenotype and WNT. The 
“competitive test”, in which we compared to randomly generated sets of genes, showed a significant 
enrichment of genetic variants associated with the phenotype in the WNT gene-set compared to 
random gene sets (empirical p=0.037, Figure 5e inset). The conservative “self-contained” test in 
which we compared to 1,000 permutated phenotypes indicated that the WNT signalling gene-set was 
associated with our phenotype; i.e., white matter probabilistic tractography features (empirical 
p=0.064; Figure 5e histogram & inset). We performed a gene-by-gene analysis of SNPs within the 
WNT signalling gene-set to investigate which genes might be predominantly contributing to the 
collective pathway enrichment signal. This test highlighted a group of 10 genes with individual 
significant association with the tractography phenotype (empirical p≤0.05, 1,000 permutations). 
These ten genes included 8 associated with Wnt/β-catenin signalling NFATC4, CSNK1A1, MAPK10, 
WNT2B, SMAD3, FBXW11, NLK, CSNK1A1L, and 2 associated with the Wnt/Ca2+ or Wnt/PCP 
pathways, PLCB2 and WNT5A (Figure 5f; Supp Table 4). Although, we cannot determine 
specifically how these SNP variants would alter the brain phenotype we found using the Genome-
scale Integrated Analysis of gene Networks in Tissues (‘GIANT’) tool that these genes created a 
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coherent interaction network within a human brain-specific gene interaction network (Figure 5g; 
Supp Table 5). GIANT hosts searchable genome-scale functional maps of human tissues, 
integrating an extensive collection of experimental data sets from publications including expression, 
regulatory and protein data(Greene et al 2015). We also performed an exploratory investigation of 
function for the 42 SNPs from the 10 genes predominantly contributing to the collective pathway 
enrichment signal to provide information related to function. We used the Gene Effect Predictor 
within the Consortium Human Build 37 (GRCh37; hg19) tool to study the 42 SNPs, whose full details 
are given in Supp Table 6. All 42 SNPs were existing in the database and they were predicted to 
have 463 consequences on the genome (Supp Table 7). Specifically, these SNPs overlapped with 
103 separate gene transcripts, 7 of them overlapped regulatory sequences and overall 95% were 
synonymous variants and 5% were missense variants (Figure 5h). 
These linked imaging-genomic analyses demonstrate a relationship between genetic 
variation in the WNT pathway with an important clinical phenotype. They provide adjunct support for 
a causal relationship between the Wnt pathway and the brain phenotype that has been established 
with our experimental data.   
 
A Wnt pathway agonist delivered specifically to MG by a nanocarrier in vivo prevents 
neuroinflammation-mediated hypomyelination and the associated cognitive impairment 
 There is a paucity of neurotherapeutic options for damage to the preterm born infant brain 
and many other neuroinflammatory-mediated neurological disorders. We have clearly demonstrated 
a link between decreased Wnt/β-catenin pathway activation and a pro-inflammatory MG activation 
state. In addition, we have shown the relevance of this pathway in human MG and preterm infant 
brain structure. As such, we complete this study by demonstrating that the Wnt pathway is a viable 
therapeutic target. To achieve this, we specifically increased Wnt pathway activity in MG/Mφ using a 
peptide inhibitor of GSK3β, which has the effect of preventing the formation of the β-catenin 
degradation complex. We delivered this peptide to MG/Mφ in vitro and in vivo by conjugating it to a 
3DNA nanocarrier together with a fluorescent tag (Cy3)(Genisphere, PA, USA). 3DNA nanocarriers 
are interconnected monomeric subunits of DNA of approximately 200nM in diameter that are 
intrinsically capable of endosomal escape(Muro 2014). In brief, we validated that our 3DNA-peptide 
conjugate had MG specificity and immunomodulatory efficacy in vitro, that is crosses the BBB, that it 
has cell specificity in vivo, and finally that it is neurotherapeutic in vivo in our systemic-inflammation 
(IL-1β) driven model of encephalopathy of the preterm born infant.  
First, we demonstrated in vitro that 3DNA nanocarrier Cy3 tagged conjugates are specifically 
internalized by MG in mixed glial cultures (Supp Figure 5a) and by MG in primary cultures after 4 
hours of incubation (Supp Figure 5b). When 3DNA was conjugated to both Cy3 and the peptide 
L803mts, an agonist of canonical Wnt signalling via inhibition of GSK3β, it was also specifically 
internalized by MG in primary culture (Supp Figure 6a). We also used the 3DNA nanocarrier tagged 
with Cy3 to deliver a cargo of L803mts to MG/Mφ that had been activated with IL-1β in vitro. 
Treatment of primary MG with L803mts delivered with 3DNA reversed the IL-1β-induced activation of 
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the MG but had no effect on PBS-treated MG as assessed with gene expression analysis (Supp 
Figure 6b). 
Moving in vivo, we aimed to generate the proof-of-concept that the 3DNA nanocarrier 
delivering L803mts and tagged with Cy3 can be taken up by MG/Mφ and influence MG/Mφ 
phenotype. Specifically, the L803mts and Cy3 conjugated 3DNA nanocarrier or the scrambled (SCR) 
peptide control and Cy3 conjugated 3DNA nanocarrier was injected i.c.v. into P1 mice, 1 hour prior to 
our standard i.p. IL-1β injection. Four hours after i.c.v. injection, we observed Cy3 fluorescence 
exclusively co-localized with IBA-1+ staining in the periventricular white matter (Figure 6a). In the 
same paradigm, using qRT-PCR analysis of isolated CD11B+ MG/Mφ we demonstrated that i.c.v. 
delivered 3DNA loaded with L803mts and tagged with Cy3 reversed the effect of IL-1β on the 
MG/Mφ phenotype but that the 3DNA-L803mts-Cy3 had no significant effect on MG/Mφ from PBS-
treated mice (Figure 6b). As i.c.v. injections cause aggravated tissue injury we subsequently 
undertook a translationally orientated trial using i.p. delivery of Cy3-tagged 3DNA conjugated to 
L803mts.  The 3DNA L803mts Cy3 or 3DNA SCR Cy3 control was injected i.p. daily between P1 and 
P5, in parallel with PBS or IL-1β. At P5, immunofluorescence in the anterior periventricular white 
matter confirmed that 3DNA L803 mts Cy3 was specifically taken up by IBA1+ MG/Mφ (Figure 6c). 
We also assessed uptake of our 3DNA conjugate by populations of macrophage in the body after i.p. 
delivery at P5. Using the same IHC techniques that clearly shows uptake in MG/Mφ we did not find 
Cy3 positive staining in the spleen or liver (Supp Figure 5c,d).  
To validate the in vivo neurotherapeutic efficacy of our novel nanocarrier-mediated WNT 
agonist therapy, we assessed the IL-1β-induced myelination deficit by measuring Mbp mRNA. 
Treatment with i.p. 3DNA L803mts Cy3 significantly prevented the IL-1β-induced reduction in Mbp 
mRNA (Figure 6d). In order to evaluate whether this improvement in neuropathology with 
nanocarrier mediated treatment also reverses the behavioural deficits observed in adults in this 
paradigm, spatial learning and memory were assessed starting at P50. Basic behavioural parameters 
we first tested via spontaneous locomotion and rearing using actimetry and exploratory behaviour 
with an open field test. As expected no changes in these basic parameters was observed between 
groups of mice., i.e. controls (PBS+3DNA SCR Cy3), injured (IL-1β+SRC Cy3) or the treatment 
group (IL-1β+3DNA L803mts Cy3) (Supp Figure 7a,b). Spatial learning and memory was tested via 
the Barnes maze test, which assesses spatial learning over 5 days of probe trials plus short term 
memory retention at the end of the learning trials and long term memory retention 10 days later. 
Spatial learning (i.e., distance travelled and number of errors) itself was not modified by IL-1β 
exposure (Figure 6e). However, mice exposed to IL-1β had a short-term memory deficit based on a 
decreased distance travelled in the target sextant during the first 30 seconds of the probe trial on the 
final day of testing (Figure 6f). In addition, IL-1β exposure caused deficits in long term memory 
recall, as assessed as the increased distance travelled in a single probe trial at 10 days post-learning 
(Figure 6g). These short term and long term neuroinflammatory induced memory deficits were both 
reversed by i.p. treatment by delivery to MG/Mφ of the Wnt antagonist, L803 mts (3DNA L803 mts 
Cy3) by the 3DNA nanocarrier (Figure 6f,g).  
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Altogether these data clearly demonstrate that a Wnt agonist therapy can reduce pro-
inflammatory MG/Mφ activation and improve neuropathological and functional outcomes in a model 
of neuroinflammation mediated white matter injury. These data also highlight a novel 3DNA 
nanocarrier that has the ability to deliver therapies like this in vivo specifically to MG.  
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Discussion 
 Recent research has highlighted that microglia of the developing brain have a unique 
phenotype. The aims of this study were, the identification in MG of the developing brain of the 
molecular regulators of injury-related phenotype, and validation of these as therapeutic targets for 
preventing microglia-mediated injury in the 15 million infants born preterm every year. We undertook 
a comprehensive set of studies involving pharmacologic and genetic manipulations in mouse and 
zebrafish models, human tissue and patient data. We also introduced an innovative 3DNA 
nanocarrier that can deliver drugs specifically to microglia in vivo. Initially, we characterised the 
complex MG/Mφ phenotype in our mouse model of encephalopathy of prematurity(Favrais et al 2011, 
Krishnan et al 2017, Schang et al 2014) and demonstrated that MG/Mφ activation is directly 
responsible in this model for the clinically relevant myelination defect. Next, using a genome-wide 
transcriptomic analysis of these activated MG/Mφ we associated the Wnt pathway with MG/Mφ 
activation. We specifically determined that the expression of Wnt/β-catenin pathway receptors, 
ligands and intracellular signalling components were robustly down-regulated in MG/Mφ isolated from 
our animal model. A combination of approaches in zebrafish and mouse models in vitro and in vivo 
allowed us to determine that Wnt/β-catenin pathway inhibition specific to MG/Mφ is sufficient and 
necessary to induce in these cells a pro-inflammatory activation, and subsequent hypomyelination in 
vivo. We highlighted the relevance of the WNT pathway to the activation state of human primary MG, 
and preterm born infant brain development. Of note, we verified our prediction that genetic variation 
in the WNT pathway in preterm infants is related to indices of their cerebral structural connectivity, 
although it is a limitation of these types of human studies that the data is not cell specific. Finally, we 
selectively delivered to MG/Mφ in vivo a Wnt pathway activator using a 3DNA nanocarrier, which we 
administered via non-invasive i.p. injection. This specific and non-invasive delivery of a Wnt agonist 
therapeutic prevented a pro-inflammatory MG/Mφ activation state and the associated white matter 
damage and cognitive deficit in our mouse model. Together, these data demonstrate that down-
regulation of the canonical Wnt/β-catenin pathway triggers an oligodendrocyte-damaging MG 
phenotype, and validate this pathway as a novel and clinically viable neurotherapeutic target thanks 
to the MG/Mφ-specificity of 3DNA nanocarriers.  
Our evidence supports that the Wnt pathway controlling MG/Mφ phenotype is the canonical 
Wnt/β-catenin pathway. Our supporting data include that genetic and pharmacological manipulation 
of the β-catenin degradation complex via Axin2 robustly effected MG/Mφ phenotype in vitro and in 
vivo. In contrast, blockade of non-canonical Wnt signalling with a PKC inhibitor had no effect on MG 
activation. Although, we acknowledge that there may still be a role for other facets of non-canonical 
signalling in the complexity of MG/Mφ functions. However, MG/Mφ-specific β-catenin ablation in vivo 
in-of-itself was sufficient to recapitulate the systemic-inflammation-driven hypomyelination that we 
see in our animal model of encephalopathy of prematurity. We also found that the WNT genes with 
variance associated with preterm infant connectivity were predominantly (8/10) from the Wnt/β-
catenin pathway.  A key role for β-catenin would also begin to explain our observations of Wnt-
mediated pro-inflammatory activation via TLR-4 and IL-1 receptor agonists and also conversely Wnt-
mediated anti-inflammatory activation via a IL-4 receptor agonist. Down-stream signalling of both the 
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TLR/IL-1 and IL-4 receptor families includes activation of the transcription factor NF- κB (nuclear 
factor kappa-light-chain-enhancer of activated B cells)(Caamano & Hunter 2002). The ability of NF-
κB to mediate the opposing effects of these receptors on MG phenotype is conferred by interactions 
with other regulatory factors, including at multiple levels indirectly and directly by β-catenin(Ma & 
Hottiger 2016).  
Ours is the first study to demonstrate a robust cell-intrinsic role of the Wnt/β-catenin pathway 
in MG activation in vitro and in vivo and validate that this pathway is a viable immunomodulatory 
neurotherapeutic. Previous work on Wnt and MG has been limited to in vitro ligand-receptor 
interactions, specifically WNT3a or WNT5a. However, the specific Wnt pathway activated by a Wnt 
ligand is dependent on the context of ligand-receptor interaction not only cell-intrinsic properties(van 
Amerongen et al 2008). This fact likely explains the discordance between the data from the previous 
studies, where in some paradigms Wnt exposure is anti-inflammatory(Halleskog et al 2012, Yu et al 
2014) or in others the exposure was pro-inflammatory(Halleskog et al 2011, Halleskog & Schulte 
2013, Hooper et al 2012) with no relation to the predicted canonical or non-canonical pathway being 
activated. Altogether these data highlight the difficulty that would be faced in using ligand-receptor 
interactions to target the Wnt pathway to modulate MG activity, in contrast with our success of 
targeting the intracellular cascade of Wnt/β-catenin pathway specifically using our 3DNA-mediated 
delivery system. 
The 3DNA nanocarrier is a powerful translational tool as is it can take agents across the BBB 
following i.p. injection, is specifically internalized by MG/Mφ in the brain and it has no toxicity in vitro 
or in vivo in our study, or in human retinal tissue in vitro(Gerhart et al 2017) and in pre-clinical in vivo 
targeted delivery of a ovarian cancer therapy(Huang et al 2016). Wnt activation in OPCs has 
previously been suggested to block their maturation by a member of our current research 
team(Fancy et al 2011). As such it was important that 3DNA-nanocarriers allowed us to target this 
pathway exclusively in MG/Mφ. 3DNA has a non-injury dependent mechanism of traversing the BBB, 
as it crossed in naïve and inflammation-exposed mice, although the specific mechanism is unknown. 
We have previously reported that the BBB in our mouse model of encephalopathy of prematurity is 
primarily intact(Krishnan et al 2017). The chemical and physical attributes of 3DNA likely precludes it 
from entering the brain via paracellular aqueous routes or transcellular lipophilic pathways. However, 
investigations of receptor mediated transcytosis are underway, as similar aptamer-based DNA 
duplexes can interact with receptors such as nucleolin or transferrin(Reyes-Reyes et al 2010).  
In preterm infants, it is exposure to difficult to identify or prevent inflammatory events, such as 
chorioamnionitis and sepsis, that is the leading risk factor for white matter damage. This damage is 
caused by microglia-mediated neuroinflammatory processes(Hagberg et al 2015). White matter 
damage in these infants is observed as reduced structural connectivity on MRI(Shah et al 2008). This 
reduced structural connectivity is in turn strongly associated with poor neurodevelopmental 
outcomes(Ball et al 2015, Woodward et al 2006). As such, the purpose of our imaging-genomics 
analysis was to link these facts and to determine if genetic variance that could alter the microglial 
inflammatory response in our preterm cohort would be linked to changes in structural connectivity. 
Our integrated analysis of imaging and genomics demonstrated that common genetic variation in 
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WNT pathway genes does indeed influence brain structural connectivity features within our preterm 
born infants. We fully acknowledge that the data we derived is not cell specific. However, it supports 
in contemporaneous infants the relevance of the WNT pathway using an imaging modality that is 
currently used to assess injury and predict outcome. In addition, we found that the WNT pathway 
genes containing SNPs associated with white matter tractography phenotype belonged to a human 
brain-specific gene interaction network. This network further builds a case for a functional effect of 
WNT SNPs in human preterm infants, with consequences for the development of white matter 
structure(Greene et al 2015). Specific prediction of the consequences of our identified SNPs found 
the majority were intron variants. Previous studies in experimental animals has shown that immune 
cell intron variants often effect cell function by altering enhancer binding(Farh et al 2015). Altogether 
our clinical data build a case that these WNT pathway SNPs may be a useful way to stratify infants 
who are at highest risk for white matter damage, and to improve on our currently limited prognostic 
abilities related to long term outcome. 
In conclusion, the activity of the Wnt/β-catenin pathway regulates MG/Mφ activation, the Wnt 
pathway is relevant in human brain development, and specific agonism of the Wnt/β-catenin pathway 
in MG/Mφ in vivo using 3DNA nanocarrier-mediated drug-delivery has a beneficial effect on MG/Mφ 
phenotype, myelination and cognitive deficits. This is strong evidence that Wnt signalling modulation 
may be a promising therapeutic approach in encephalopathy of prematurity and, potentially, in other 
disorders involving MG/Mφ-mediated neuroinflammation.  
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Methods 
Study approval 
Experimental protocols were approved by the institutional guidelines of the Institut National de la 
Santé et de la Recherché Scientifique (Inserm, France) (2012-15/676-0079), and met the guidelines 
for the United States Public Health Service’s Policy on Humane Care and Use of Laboratory Animals 
(NIH, Bethesda, Maryland, USA).  
The EPRIME study was reviewed and approved by the National Research Ethics Service, and all 
infants were studied following written consent from their parents. 
For human MG cell culture, all procedures had ethical approval from Agence de Biomédicine 
(Approval PFS12-0011). Written informed consent was received from the tissue donor. 
 
Nomenclature of MG phenotype  
We have adopted nomenclature consistent with our previous work in primary MG(Chhor et al 2013) 
acknowledging that this is a simplification necessary to facilitate description of the data. To simplify, 
we distinguished 3 types of phenotypes according to the mRNA expression levels of markers listed in 
brackets: Pro-inflammatory (Nos2, Ptgs2, Cd32, Cd86 and Tnfα), anti-inflammatory (Arg1, Cd206, 
Lgals3, Igf1, Il4 and Il10) and immunoregulatory (Il1rn, Il4ra, Socs3 and Sphk1). 
 
Mice 
Experiments were performed with male OF1 strain mice pups from adult females purchased from 
Charles River (L’Arbresle, France) or Transgenic (Tg) male mice born in our animal facility. See the 
justification below in animal model section regarding use of male mice only. Tg mice B6.129P-
Cx3cr1tm1Litt/J (CX3CR1-GFP) mice, B6.129-Ctnnb1tm2Kem/KnwJ (β-cateninlfox) mice and B6.129P2-
Lyz2tm1(cre)Ifo/J (LysMCre) mice were purchased from The Jackson Laboratory (ME, USA). CX3CR1-
GFP mice express EGFP in monocytes, dendritic cells, NK cells, and brain MG under control of the 
endogenous Cx3cr1 locus. Only heterozygous (Cx3cr1GFP/+ and β-cateninΔ/+) mice were used in this 
study. Cx3cr1GFP/+ are obtained by crossing Cx3cr1GFP/GFP with C57bl6J (WT) mice. LysMCre mice are 
useful for Cre-lox studies of the myeloid cell lineage. Here, we used it to analyse β-catenin deficit in 
the brain MG by crossing β-cateninflox with LysMCre mice. Control mice were obtained by crossing β-
cateninflox with C57bl6J (WT) mice. 
 
Transgenic fish lines and fish maintenance 
Tg (pu1::Gal4-UAS-TagRFP)(Sieger et al 2012) fish were kept at 26.5 °C in a 14 hour light/10 hour 
dark cycle. Embryos were raised at 28.5 °C in E3-solution until 120 hpf for analyses.  
 
Drugs 
Mouse cytokines (IL-1β, IL-4) were purchased from R&D systems (France). LPS-EB Ultrapure was 
purchased from InvivoGen (France). To inhibit the Wnt/β-catenin pathway, we used XAV939 (Sigma-
Aldrich, France). To activate it, we used CT99021 (Selleckchem, TX, USA), Lithium Chloride (Sigma-
Aldrich, France), L803mts (Tocris, UK). The L803mts peptide and a scrambled peptide (SCR) were 
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purchased conjugated to short oligonucleotide with disulphide bond linker from BioSynthesis (TX, 
USA) then hybridized to Cy3-labelled 3DNA at Genisphere (PA, USA). Chelerythrine was purchased 
from Sigma-Aldrich. 
 
Model of Encephalopathy of prematurity induced by IL-1β  
Mice were housed under a 12-hour light-dark cycle, had access to food and water ad libitum and 
were weaned into same sex groups at P21. On P1 pups were sexed and where necessary litters 
were culled to 6-8 (Tg mice) or 12 (OF1 mice) pups. Assessments of injury and outcomes were made 
only in male animals and all pups within a litter received identical treatment to reduce any effects of 
differing maternal care. IL-1β exposure was carried out as previously described(Favrais et al 2011). 
Male mice only are used, as only male pups display a myelin deficit following exposure to IL-1β in 
this paradigm. This higher severity of injury in male animals is in accordance with observations of a 
greater burden of neurological injury in male infants following perinatal insult (Johnston & Hagberg 
2007). A 5 μl volume of phosphate-buffered saline (PBS) containing 10 μg/kg/injection of 
recombinant mouse IL-1β (R&D Systems, MN, USA) or of PBS alone (control) was injected intra-
peritoneally (i.p.) in male pups twice a day (morning and evening) on days P1 to P4 and once in the 
morning at P5.  
 
Morphological analysis of MG  
P1 and P3 brain from Cx3Cr1-GFP mice administered PBS or IL-1β were fixed for 24 hours in 4% 
buffered formalin (QPath, Labonord SAS, France). Following fixation, cerebral tissue was sliced 
along a sagittal plane on a calibrated vibratome (VT1000 S, Leica, Germany) into 100 µm thick free-
floating slices. Morphological analysis of MG was assessed as previously described(Verdonk et al 
2016), using spinning disk confocal system (Cell Voyager - CV1000, Japan) with a UPLSAPO 
40x/NA 0.9 objective and the use of a 488-nm laser. A mosaic of more than one hundred pictures 
covering approximately 3.17 mm² of tissue (cortex and white matter) per brain. An automatic image 
analysis using a custom designed script developed with the Acapella™ image analysis software 
(version 2.7 - Perkin Elmer Technologies) was realize to obtain density, cell body area, number of 
primary, secondary and tertiary processes and the area covered by the MG processes in 2D. A 
complexity index was calculated to analyse the morphological modifications induced by IL-1β. 
 
Neural tissue dissociation and CD11B+ MG or O4+ oligodendrocytes magnetic-activated cell sorting  
At P1, P2, P3, P5 and P10, brains were collected for cell dissociation and CD11B+ cell separation 
using a magnetic coupled antibody anti-CD11B (MACS Technology), according to the manufacturer’s 
protocol (Miltenyi Biotec, Germany) and as previously described(Schang et al 2014). In brief, mice 
were intracardially perfused with NaCl 0,9%. After removing the cerebellum and olfactory bulbs, the 
brains were pooled (n=2-3 per sample) and dissociated using the Neural Tissue Dissociation Kit 
containing papain and the gentleMACS Octo Dissociator with Heaters. MG were enriched using the 
anti-CD11B (MG) MicroBeads, pelleted and conserved at -80 °C. The purity of the eluted CD11B+ 
fraction was verified as previously described (15). At P5 and P10, brains were collected for, O4+ 
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oligodendrocytes cell separation using a magnetic coupled antibody anti-O4 (MACS Technology), 
according to the manufacturer’s protocol (Miltenyi Biotec, Germany) and as previously described 
(Schang et al 2014). 
 
RNA extraction and quantification of gene expression by real-time qPCR 
Total RNA was extracted with the RNeasy mini kit according to the manufacturer’s instructions 
(Qiagen, France). RNA quality and concentration were assessed by spectrophotometry with the 
NanodropTM apparatus (Thermofisher Scientific, MA, USA). Total RNA (500ng) was subjected to 
reverse transcription using the iScriptTM cDNA synthesis kit (Bio-Rad, France). RT-qPCR was 
performed in triplicate for each sample using SYBR Green Super- mix (Bio-Rad) for 40 cycles with a 
2-step program (5 s of denaturation at 95°C and 10 s of annealing at 60°C). Amplification specificity 
was assessed with a melting curve analysis. Primers were designed using Primer3 plus software 
(See sequences in Supp Table 8). Specific mRNA levels were calculated after normalization of the 
results for each sample with those for Rpl13a mRNA (reference gene). The data are presented as 
relative mRNA units with respect to control group (expressed as fold over control value). 
 
 
Immunohistofluorescence 
For frozen sections, P5 mice were intracardially perfused with 4% paraformaldehyde in 0.12M 
phosphate buffer solution under isoflurane anaesthesia. Brains were then post-fixed in 4% 
paraformaldehyde (Sigma-Aldrich, France) overnight at 4°C After 2 days in 30% sucrose 0.12M 
phosphate buffer solution, brains were frozen at -45°C in isopentane (Sigma-Aldrich) before storage 
at -80°C until sectioning on a cryostat (thickness14μM). Immunohistofluorescence was performed as 
previously described(Miron et al 2013). Slides were permeabilized and blocked for 1 hour and 
primary antibody was applied overnight at 4 °C in a humid chamber. To detect MG, rabbit antibody to 
IBA1 (Wako, 1: 500) was used. To detect proinflammatory MG we used mouse antibody to iNOS (BD 
Biosciences, 610329, 1:100), rat antibody to CD16/CD32 (BD Pharmingen, 553141, 1:500), rabbit 
antibody to COX2 (Abcam, Ab15191, 1:500). To detect anti-inflammatory MG, we used goat antibody 
to Arginase-1 (ARG1) (Santa Cruz Biotechnology, sc-18355, 1:50), rabbit antibody to mannose 
receptor (MR) (Abcam, ab64693, 1:600). To detect MG and Mφ rat antibody to CD68 (Abcam, 
ab53444, 1:100) was used. Fluorescently conjugated secondary antibody to goat IgG (A21432), 
antibodies to rabbit IgG (A11034, A10042), antibodies to rat IgG (A21434, A11006, A21247) and 
antibody to mouse IgG (A21042), were applied for 2 hours at 20–25 °C in a humid chamber (1:500, 
Invitrogen). Following counterstaining with Hoechst, slides were coverslipped with Fluoromount-G 
(Southern Biotech, Cliniscience, France). Antibody isotype controls (Sigma-Aldrich) added to 
sections at the same final concentration as the respective primary antibodies showed little or no 
nonspecific staining. All manual cell counts were performed in a blinded manner. 
 
In vivo treatments with XAV939, 3DNA L803mts Cy3, and Gadolinium 
XAV939 (250μM, 0.5nmol/injection) or PBS/DMSO (vehicle) and 3DNA L803mts Cy3 
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/334359doi: bioRxiv preprint first posted online May. 31, 2018; 
 20
(200ng/injection) or 3DNA SCR Cy3 (200ng/injection) (control peptide) were injected into the right 
ventricle of mice pups at P1 using 26-G needle linked to a 10μL Hamilton syringe mounted on a 
micromanipulator and coupled to a micro-injector (Harvard Apparatus, MA, USA; outflow 2 μL/min), 
3DNA SCR or L803 mts Cy3 were injected 1 hour before i.p. injection of PBS or IL-1β. Three hours 
after PBS or IL-1β injection or 4 hours after XAV939 or vehicle injection, pups were sacrificed for 
CD11B-postive cell sorting. Chronic treatment with 3DNA L803mts Cy3 were performed by i.p. co-
injections of PBS or IL-1β with 3DNA L803mts Cy3 (500ng/injection) or 3DNA L803mts Cy3 
(500ng/injection) twice a day between P1 and P3 and once a day at P4 and P5. Effect of this 
treatment on myelination was analysed at P10 and behavioural tests were realized in adulthood (2-
3months). To analyse uptake of 3DNA in liver and spleen, one i.p. injection of 3DNA Cy3 
(500ng/injection) with PBS or IL-1β was performed and animals sacrificed 4 hours later. To analyse 
uptake of 3DNA in brain, animals was sacrificed 4 hours after i.c.v. injection at P1, and at the end of 
the i.p. treatment at P5. 
 
Selective depletion of pro-inflammatory MG in white matter injury was performed using gadolinium 
chloride (GdCl3) as previously described(Miron et al 2013) with slight modifications. Briefly, PBS or 
Gadolinium (200nmol/injection, Sigma, France) was injected into the corpus callosum of mice pups at 
P1, 1 hour before i.p. injections of PBS or IL-1 β using 26-G needle linked to a 10μL Hamilton syringe 
mounted on a micromanipulator and coupled to a micro-injector (Harvard apparatus, outflow 2 
μL/min). Effect of pro-inflammatory MG depletion on MG cell phenotype and myelination was 
analysed at P10. 
 
Actimetry 
The horizontal (spontaneous locomotion) and vertical (rearing) activities were individually assessed 
in transparent activity cages (20x10x12cm) with automatic monitoring of photocell beam breaks 
(Imetronic, Bordeaux, France). Actimetry test was performed at ≈ 2 months (day 65), with recording 
every 30 minutes over 23 hours, in order to evaluate the effect of IL-1β and 3DNA treatments i.p. 
injections on spontaneous locomotor activity, as modified locomotor activity could lead to biased 
results from other behavioural tests requiring locomotion. 
 
Open-field 
The open-field test was performed at ≈ 2.5 months (day 80) using a square white open-field 
apparatus (100x100x50cm) made of plastic permeable to infrared light. Distance travelled and time 
spent in inactivity were recorded by a videotrack system (Viewpoint®) during the 9 minutes’ test. 
 
Barnes maze test 
The Barnes maze test was performed at 3 months (day 90 to 94). The maze is a wet, white and 
circular platform (80cm diameter), brightly illuminated (400lux), raised 50cm above the floor, with 18 
holes (4.5cm) equally spaced around the perimeter. A white hidden escape box (4x13x7cm), 
representing the target, was located under one of the holes. Prior to the test, each mouse was 
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subjected to a habituation trial where the mouse was directly put in the escape box for 30 seconds. 
Learning: the mouse was placed in the centre of the circular maze and was allowed to explore the 
platform and holes for 3 minutes’ maximum. The distance travelled was recorded using a videotrack 
system (Viewpoint®). Latency to reach the escape box, and number of errors (number of empty 
holes visited) were manually noted. When the mouse found and entered the escape box, the 
videotrack recording was stopped, and the mouse remained in the escape box for an additional 10 
seconds before returning to its home cage. If the mouse did not enter spontaneously, it is gently put 
toward the escape box, before returning to its home cage. On the first day of training, mice 
underwent 2 trials after the habituation trial; thereafter, 3 trials were given per day, with a 2 hours’ 
interval. 
Probe trial: on the 5th day of learning, the probe trial, with the escape box removed and lasting 90 
seconds, is used to assess spatial memory performances. Time spent and distance travelled in each 
sextant (defined by one of the 6 parts of the maze, that includes 3 holes) were recorded. The target 
zone is defined as the part, which contains the target hole and two adjacent holes. 
Long term trial: 15 days after learning, a new trial, with the escape box, is used to assess long-term 
retention memory. Escape latency and distance travelled to reach the target were recorded. 
 
Immunohistochemistry 
Brains were collected at P15 or P30 and immersed immediately after sacrifice in 4% formaldehyde 
for 4 days at room temperature, prior to dehydration and paraffin embedding. Section was realized 
using a microtome. Immunostaining was performed as previously described(Favrais et al 2011) using 
mouse antibody to Myelin Basic Protein (MAB382, Millipore, France). The intensity of the MBP 
immunostaining in corpus callosum was assessed by a densitometry analysis through NIH ImageJ 
Software (http://imagej.nih.gov/ij/). Optical density was deduced from grey scale standardized to the 
photomicrograph background. Corpus callosum was defined as region of interest. One measurement 
per section and 4 sections were analysed in each brain. 
 
Primary mouse MG culture  
Primary mixed glial cell cultures were prepared from the cortices of postnatal day 1 OF1 mice, as 
previously described(Chhor et al 2013). After 14 days, MG were purified and pelleted via 
centrifugation and re-suspended in DMEM/PS/10% FBS at a concentration of 4x105 cells/mL. One or 
two mL/well of cell suspension was plated in 12-well (for qRT-PCR) or 6-well (for ELISA) culture 
plates respectively. For immunofluorescence, 250 μL of cell suspension was plated in µ-Slide 8 Well 
Glass Bottom (Ibidi, Biovalley, France). Post-plating, media was replaced after 1 hour. Based on 
previous work from our lab(Chhor et al 2013), the day after plating, MG were exposed for 4 hours to 
DMEM (control) or IL-1β at 50 ng/mL, IL-4 at 20 ng/mL, diluted in DMEM. For RT-qPCR or ELISA 
analysis, media were removed and plates frozen at -80°C. For immunofluorescence experiments, 
cells were fixed at room temperature with 4% paraformaldehyde for 20 minutes.  
 
Mixed mouse glial and OPC cultures 
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Cortical mixed glial cultures and purified OPC were obtained from the cortices of postnatal day 1 OF1 
mice as previously described with slight modification (40). Mixed glial cells were resuspended in 
MEM-C, which consists of Minimal Essential Medium (MEM) supplemented with 10% FBS (Gibco), 
Glutamax (Gibco), and 1% PS, and plated at 2x105 cells/cm2 onto T75 flasks for subsequent OPC 
purification or Ibidi 8-well chamber slides (Biovalley, France) for mixed glial culture treatment. For this 
purpose, mixed glial cultures were maintained in proliferation in MEM-C for 7 days, then maintained 
during 10-12 days in differentiation medium which consists of Dulbecco's Modified Eagle Medium 
(DMEM-F12) with glutamine (Gibco), N2 (Gibco) and 1% PS. Half of the wells were exposed to IL-1β 
(50 ng/ml) and medium was changed every 2-3 days. Alternatively, mixed glial cultures plated onto 
T75 flasks were maintained for 9-12 days in MEM-C and purified OPC cultures were prepared by a 
differential shake(McCarthy & de Vellis 1980). OPCs were seeded onto Ibidi 8-well chamber slides at 
a density of 3 x 104 cells/cm2 in proliferation medium which consists of MACS Neuro Medium with 
Neurobrew 21 (Miltenyi Biotec), Glutamax, 1% PS, FGFb and PDGFa (10 ng/ml each, Sigma, 
France). After 72h, differentiation was induced by FGFb and PDGFa withdrawal and by adding T3 
(40 ng/ml, Sigma). Half of the wells were exposed to IL-1β (50 ng/ml). After 10-12 days (for mixed 
glial cultures) or 72h (for OPCs) of IL-1β, cells were fixed 20 min with 4% paraformaldehyde.  
 
Primary human MG culture  
Within 1 hour of scheduled termination (age 19 and 21 weeks of amenorrhea) brain tissues were 
collected from two human foetuses without any neuropathological alterations. Brain tissue (4 g) was 
minced and further mechanically dissociated using 1ml micropipettor in HBSS with Ca2+ and Mg2+. 
Using a 70μM strainer a single cell suspension was obtained. MG/Mφ isolation were obtained using 
anti-CD11B (MG) microbeads (MACS Technology), according to the manufacturer’s protocol 
(Miltenyi Biotec, Germany), as above. CD11B+ MG/Mφ were pelleted via centrifugation and re-
suspended in DMEM/PS/10% FBS at a concentration of 5x106 cells/mL. Cells were plated in 12-well 
plates (1ml/well) for qRT-PCR analysis. For immunofluorescence analysis, cells were plated in µ-
Slide 8 Well Glass Bottom (Ibidi, Biovalley, France). 48 hours after plating, MG were exposed for 4 
hours to DMEM (control) or LPS 10 ng/mL diluted in DMEM. For RT-qPCR media were removed and 
plates frozen at -80°C. For immunofluorescence experiments, cells were fixed at room temperature 
with 4% paraformaldehyde for 20 minutes. 
 
Immunocytofluorescence 
Immunofluorescence staining was performed as previously described(Favrais et al 2011), using 
mouse antibody to MBP (MAB382, 1: 500; Millipore), rabbit antibody to OLIG2 (18953, 1:500 IBL-
America, MN, USA), rabbit antibody to beta-catenin (E247, 1:100; Millipore), rabbit antibody to COX2 
(Ab15191, 1: 400; Abcam, MA, USA) goat antibody to ARG1 (sc 18354, 1:400; Santa-Cruz, CA , 
USA) and IL1RA (sc 8482, 1:200, Santa-Cruz). Fluorescently conjugated secondary antibody (all 
Thermfisher Scientific) to mouse IgG (A21236), to rabbit IgG (A21206) and to goat IgG (A11055), 
were applied for 2 hours at 20–25 °C in a humid chamber (1:500, Invitrogen). Slides were 
coverslipped with Fluoromount-G (Southern Biotech, AL, USA). To analyse MBP labelling, MBP area 
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was assessed as the percentage of total area above threshold using NIH ImageJ software 
(http://imagej.nih.gov/ij/) and was normalized to the number of Olig2-positive cells. Means were 
expressed as fold change over control condition. 
 
Microarrays and data pre-processing 
Gene expression quantification, including RNA extraction and quality assurance, was performed by 
Miltenyi Biotec on a total of 24 samples of CD11B+ cells and 20 samples of O4+ cells from the brains 
of mice exposed to IL-1β or PBS between P1 and P5, and sacrificed at P5 or P10. RNA was 
extracted and hybridised to Agilent Whole Mouse Genome Oligo Microarrays (8x60K).  
 
Bioinformatics’ gene co-expression network reconstruction 
Expression data 
Each cell type and experimental condition was analysed separately, to investigate changes in gene 
expression over time in response to exposure to IL-1β or PBS. Expression values for MG (CD11B+) 
and oligodendrocytes (O4+) at P5 and P10 were quantile normalized. 
Differential expression 
Probes showing high variability across time points within each cell type were retained for further 
analysis (coefficient of variation above 50th centile). Probes showing differential expression between 
time points were identified using unpaired t-tests with Benjamini-Hochberg correction for multiple 
testing in the Bioconductor multitest package(Opgen-Rhein & Strimmer 2007, Schafer & Strimmer 
2005) 
(Gentleman et al 2004), with a false discovery rate threshold (FDR) of 10%. 
Network reconstruction 
The co-expression network was inferred using Graphical Gaussian Models (GGM), implemented 
within the software package “GeneNet”(Schafer & Strimmer 2005) in R (http://www.r-project.org/). 
This analysis computes partial correlations, which are a measure of conditional independence 
between two genes i.e. the correlation between the expression profiles of two genes after the 
common effects of all other genes are removed. Correction was made for multiple comparisons by 
setting the local false discovery rate (FDR) at ≤1%. Individual networks were reconstructed for 
temporally differentially expressed genes for each cell type in each experimental condition (i.e. 2 cell 
types x 2 conditions). The input for each GGM was a matrix of differentially expressed normalised 
mRNA transcript levels. The genes in each of these four co-expression networks (Supp Figure 3e) 
were functionally annotated by calculating significant enrichment of KEGG pathways using the Broad 
Institute MSigDB database (http://software.broadinstitute.org/gsea/msigdb/index.jsp)(Subramanian et 
al 2005) (Supp Table 2). 
Differential expression analysis was performed using the limma package (Smyth 2004). The mouse 
datasets were annotated with human Ensembl gene ID using the biomaRt Bioconductor R 
package(Durinck et al 2009)  and selecting human genes that were ‘one-to-one’ orthologues with 
mouse genes. We multiplied the adjusted P value (the –log10 of P value) by the log-transformed fold 
change to generate a gene-level score, which was used as a metric to ‘rank’ genes. GSEA 
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(Subramanian et al 2005) was applied genome-wide to the ranked list of gene scores (reflecting both 
the significance and the magnitude of expression changes in IL-1β exposed MG/Mφ) to test if a 
group of genes (MSigDB gene sets) occupy higher (or lower) positions in the ranked gene list than 
what it would be expected by chance. Gene set enrichment scores and significance level of the 
enrichment (NES, P value, FDR) and enrichment plots were provided in the GSEA output format 
developed by Broad Institute of MIT and Harvard (permutations=10,000). The GSEA was carried 
out accounting for the direction of IL-1β effect, i.e. considering whether a gene is upregulated or 
down-regulated under IL-1β exposure at P5 and P10.  
 
Wnt/β-catenin pathway modulation in primary MG 
MG transfection was realized using negative control siRNA or siRNA Axin2 (ON TARGET Plus 
Control Pool and ON TARGET Plus mouse Axin2-06, Thermoscientific, Dharmacon, France) at a 
final concentration of 30μM. Transfection was realized using the MACSfectin transfection reagent 
(Miltenyi biotec, Germany) in mixture of Opti-MEM and DMEM mediums for 48 hours prior to IL-1β 
stimulation. Axin2 mRNA knockdown was evaluated by qRT-PCR. XAV939 and CT99021 (1μM) or 
PBS/DMSO (vehicle) were added to media 30 minutes before DMEM (control) or IL-1β (50 ng/ml) 
treatments. 
 
PSer45 β-Catenin and β-Catenin quantification by ELISA 
Quantification of PSer45 β-Catenin and β-Catenin by ELISA was realized using β-catenin pSer45 + 
Total PhosphoTracer ELISA Kit (ab119656, Abcam) for primary microglia or β-catenin ELISA Kit 
(ab1205704, Abcam) for MACSed cells. Briefly, cell lysates were obtained using lysis buffer of the kit. 
Total protein level was quantified using BCA method (Bicinchoninic Acid Solution and Copper (II) 
Sulfate Solution from Sigma, France). The ELISA was realized according to the manufacturer’s 
instruction. Quantification of PSer45 β-Catenin is a ratio PSer45 β-Catenin/total β-Catenin. Total β-
Catenin was normalized using total protein level. Total β-Catenin data are expressed as fold over 
control values. 
 
Wnt/β-catenin pathway modulation in Zebrafish. 
MG were visualized using pu1::Gal4-UAS::TagRFP. 72 hpf old zebrafish embryos were used for LPS 
microinjection (5ng/injection) in hindbrain. The Wnt/β-catenin pathway was modulated by adding 
LiCl (80mM), XAV939 (5µM), CT99021 (3µM) in E3-solution. Fluorescently labelled embryos were 
imaged using a microscope equipped with an ApoTome system (Zeiss, France) fitted with an 
AxioCam MRm camera (Zeiss) controlled by the Axiovision software. The thickness of the z stacks 
was always comprised between 2.5 and 3 µm. Fluorescence intensity was quantified by NIH ImageJ 
software (http://imagej.nih.gov/ij/) on grey scale images.  
 
Preterm infant cohort 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Preterm infants were recruited as part of the EPRIME (Evaluation of Magnetic Resonance (MR) 
Imaging to Predict Neurodevelopmental Impairment in Preterm Infants) study and were imaged at 
term equivalent age over a 3-year period (2010-2013) at a single centre. The EPRIME study was 
reviewed and approved by the National Research Ethics Service, and all infants were studied 
following written consent from their parents. 290 infants (gestational age 23.57 to 32.86 weeks, 
median 30 weeks) were scanned at term-equivalent age (38.29 to 58.28 weeks). Pulse oximetry, 
temperature, and heart rate were monitored throughout the period of image acquisition; ear 
protection in the form of silicone-based putty placed in the external ear (President Putty, Coltene, 
UK) and Mini-muffs (Natus Medical Inc., CA, USA) were used for each infant. 
 
Image Acquisition  
MRI was performed on a Philips 3-Tesla system (Best, Netherlands) using an 8-channel phased 
array head coil. The 3D-MPRAGE and high-resolution T2-weighted fast spin echo images were 
obtained before diffusion tensor imaging. Single-shot EPI DTI was acquired in the transverse plane in 
32 non-collinear directions using the following parameters: repetition time (TR): 8000 ms; echo time 
(TE): 49 ms; slice thickness: 2 mm; field of view: 224 mm; matrix: 128 × 128 (voxel size: 1.75 × 1.75 
× 2 mm3); b value: 750 s/mm2. Data were acquired with a SENSE factor of 2. 
 
Data selection and quality control  
The T2-weighted MRI anatomical scans were reviewed in order to exclude subjects with extensive 
brain abnormalities, major focal destructive parenchymal lesions, multiple punctate white matter 
lesions or white matter cysts. All MR-images were assessed for the presence of image artefact 
(inferior-temporal signal dropout, aliasing, field inhomogeneity, etc.) and severe motion (for head-
motion criteria see below). 290 infants had images suitable for tractography and associated genetic 
information. 
DTI analysis was performed using FMRIB's Diffusion Toolbox (FDT v2.0). Images were registered to 
their non-diffusion weighted (b0) image and corrected for differences in spatial distortion due to eddy 
currents. Non-brain tissue was removed using the brain extraction tool (BET)(Smith 2002). Diffusion 
tensors were calculated voxel-wise, using a simple least-squares fit of the tensor model to the 
diffusion data. From this, the tensor eigenvalues and FA maps were calculated. 
 
Probabilistic tractography 
Regions of interest for seeding tracts were obtained by segmentation of the brain based on a 90-
node anatomical neonatal atlas(Shi et al 2011), and the resulting segmentations were registered to 
the diffusion space using a custom neonatal pipeline(Ball et al 2010). Tractography was performed 
on DTI data using a modified probabilistic tractography which estimates diffusive transfer between 
voxels(Robinson et al 2008), using cortico-cortical connections only. A weighted adjacency matrix of 
brain regions was produced for each infant: self-connections along the diagonal were removed; 
symmetry was enforced; and the redundant lower triangle removed. The edges of these connectivity 
graphs were vectorised by concatenating the rows for each individual connectivity matrix, and 
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appending them to form a single matrix of n individuals by p edges. Each phenotype matrix was 
adjusted for major covariates (post-menstrual age at scan and at birth) and reduced to its first 
principal component. 
 
Genome-wide genotyping 
Saliva samples from 290 preterm infants with imaging data were collected using Oragene DNA OG-
250 kits (DNAGenotek Inc., Kanata, Canada) and genotyped on Illumina HumanOmniExpress-24 
v1.1 chip (Illumina, San Diego, CA, USA). Filtering was carried out using PLINK (Software: 
https://www.cog-genomics.org/plink2). All individuals had missing call frequency < 0.1. SNPs with 
Hardy-Weinberg equilibrium exact test p≥1 × 10-6, MAF ≥ 0.01 and genotyping rate > 0.99 were 
retained for analysis. After these filtering steps, 659 674 SNPs remained. 
 
Preterm infant imaging genomics analysis of WNT pathway  
A list of all genes in the WNT signalling pathway (entry hsa04310) in the Kyoto Encyclopaedia of 
Genes and Genomes (KEGG) was used as a gene-set-of-interest (n=141 genes). Gene-set analysis 
was carried out with the Joint Association of Genetic Variants (JAG) tool(Lips et al 2012, Lips et al 
2015) to test the joint effect of all SNPs located in the WNT pathway. This procedure consists of 
three parts: 1) SNP to gene annotation; 2) self-contained testing (i.e. association) and 3) competitive 
testing (i.e. enrichment). An enriched pathway can be defined as one whose genes are more strongly 
associated with the phenotype than those genes outside the pathway. Phenotype permutation is 
used to evaluate gene-set significance, implicitly controlling for linkage disequilibrium, sample size, 
gene size, number of SNPs per gene, and number of genes in a gene-set. This will result in a p-value 
(with a traditional significance threshold<0.05) if there is an enrichment for variants associated with 
the phenotype within the gene-set of interest compared to random matched gene-sets.  
Following SNP-gene mapping, genes in the WNT-set were tested for association with the 
original phenotype (query data), and this was repeated with 1000 permutations of the phenotype 
(self-contained/association test). This tests the null hypothesis that no pathway genes are associated 
with the phenotype, and combines the individual gene association p-values into a single p-value for 
the entire pathway. The competitive/enrichment test was then done to test the null hypothesis that 
the pathway genes are no more associated with the phenotype than 300 randomly drawn non-
pathway gene-sets, with 1000 phenotype permutations. The association analysis was repeated 
gene-by-gene within the WNT gene-set to investigate which members of the gene-set might be 
predominantly contributing to the collective signal.  
 
Statistical analysis. 
No statistical methods were used to predetermine sample sizes but these were similar to those 
generally employed in the field. Data are expressed as the mean values +/- standard error of the 
mean (SEM). Data was first tested for normality using the Kolmogorov-Smirnov normality test for 
n=5-7 and D'Agostino & Pearson omnibus normality test for n>7. F-test (Single comparisons) or 
Bartlett's test (Multiple comparison) for analyse of variances was used. Multiple comparisons in the 
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same data set were analysed by one-way ANOVA with Newman-Keuls post hoc test, Two-way 
ANOVA with Bonferroni post hoc or Kruskal-Wallis test with Dunns post hoc. Single comparisons to 
control were made using two-tailed Student's t-test or Mann-Whitney test. P < 0.05 was considered 
to be statistically significant. For the Barnes maze probe trial, univariate t test was performed to 
compare the % time spent in the target sextant to the theoretical value 16.67 % (i.e. when the mouse 
spent equal time within each sextant). Data handling and statistical processing was performed using 
Microsoft Excel and GraphPad Prism Software. 
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Figures 
 
Figure 1. MG/Mφ are required to induce hypomyelination in our model of encephalopathy of 
prematurity. In (a) a schematic of the experimental paradigm for modelling encephalopathy of 
prematurity and also indicating the timing of analysis of MG/Mφ and oligodendrocytes (Oligo). Of 
note, experiments need to be performed between postnatal day (P1) and P5 as this is when 
oligodendrocyte maturation in the mouse matches that found in vulnerable preterm born infants, 
those born from 22-32 weeks’ gestation. In (b-e) we demonstrate that oligodendrocyte injury in our 
model is dependent on activated MG/Mφ by inducing cell death in these cells. Specifically, PBS or IL-
1β exposed mice were injected in the corpus callosum with vehicle (PBS) or gadolinium chloride, 
GdCl3; 200 nmol. Quantification in (b) of the reduced number of pro-inflammatory (IBA1+/COX2+ 
cells) and stable numbers of anti-inflammatory (IBA1+/ARG1+ cells) MG/Mφ in corpus callosum at 
P3 (n=3/group, mean±SEM, Mann-Whitney test, * p<0.05). Representative images in (c) of 
immunoreactive staining in the corpus callosum for IBA1, COX2 and Dapi in mice at P3 treated as 
described for (a) and (b) (scale bar: 100μm). Following GdCl3 treatment, at P15 in (d) quantification 
of the reduced myelin injury as shown with MBP-IR by grey density in corpus callosum (mean±SEM, 
Mann–Whitney test, * p<0.05, n given inside bar on graph), and in (e) representative images showing 
MBP immuno-reactivity (MBP-IR) (scale bar: 20μm). The requirement for the presence of MG/Mφ to 
illicit oligodendrocyte demyelination was also verified in vitro in mixed glial cultures. Oligodendrocyte 
differentiation was shown to be decreased by IL-1β exposure by analysis of MBP-IR area normalized 
by OLIG2+ cell number in (f), where mean±SEM, ** p<0.01 and n are given inside each bar on 
graph. 
 
Figure 2. MG/Mφ have a subtly altered morphology and bi-phase alterations to phenotype in 
our model of encephalopathy of prematurity. Quantification in (a) of the complexity of MG/Mφ 
ramifications and process length in CX3CR1GFP/+ mice exposed via i.p. injection to PBS or IL-1β for 3 
hours (P1) or for 48 hours (P3). The proportion (%) and absolute quantification of changes in MG/Mφ 
are shown; n=4/group, mean±SEM, Mann–Whitney test, * p<0.05. (b) Representative images of IL-
1β induced decrease in the complexity index in GFP+ MG/Mφ at P3. Scale bar: 25μm. MG/Mφ 
phenotype over time via quantification in (c) of pro-inflammatory markers (Nos2, Ptgs2, Cd32, 
Cd86, Tnfα, and Il6 mRNA), anti-inflammatory markers (Arg1, Lgals3, Cd206, Igf1, Il4 and Il10 
mRNA) and immuno-regulatory markers (Il1rn, Il4ra, Socs3 and Sphk1 mRNA) by RT-qPCR in 
CD11B+ MG/Mφ magnetically sorted from brain in PBS or IL-1β injected mice. See also Supp 
Figure 1. mRNA expression as mean±SEM of the fold change relative to PBS group. Analysis made 
with a two-way ANOVA with post hoc Bonferroni’s test (* p<0.05, ** p<0.01, *** p<0.001) and n for 
each data point is shown on the graphs in corresponding colours. 
 
Figure 3. The Wnt pathway is down-regulated in MG/Mφ isolated from our model of 
encephalopathy of prematurity and down-regulation is necessary and sufficient for MG 
activation in vitro. Analysis of microarray data from MACS purified CD11B+ MG/Mφ from IL-1β and 
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PBS administered mice was undertaken. This revealed (a) that changes in the Wnt signalling 
pathway are strongly significantly associated with MG/Mφ activation, see also Supp Figure 2. In (b) 
a cohesive network of multi-modal interactions between Wnt pathway genes in the MG/Mφ co-
expression network can be generated via analysis using the GeneMania tool network (Warde-Farley 
et al 2010). Annotation of this network with a bold red circle indicates that the gene is down-regulated 
in the microarray data at P5 and P10, genes with a finer red line are down-regulated at a single time 
point and those in purple display a switch, being significantly higher at one and significantly lower at 
the other time point. In (c) validation of robust down-regulation in MG/Mφ of mRNA expression of 
Ctnnb1, Tcf1, Lef1 and Fzd 4,6 mRNA by RT-qPCR in CD11B+ MG/Mφ MACSed from brains of PBS 
or IL-1β-exposed mice at P1, 2, 3 ,5 and 10. See also Supp Figure 3. Analysis made with a two-way 
ANOVA with post hoc Bonferroni’s test: * p<0.05, ** p<0.01 *** p<0.001, numbers of samples for 
each data point shown on the graphs in corresponding colours. In (d) quantification of β-catenin by 
ELISA in CD11B+ MG/Mφ MACSed from brains of PBS or IL-1β-exposed mice at P3. β-catenin 
protein levels were reduced and are presented as a fold change relative to PBS-injected mice, 
(mean±SEM). Analysis made with a Student’s t-test, * p<0.05. In (e) XAV939, a β-catenin pathway 
inhibitor induced a pro-inflammatory MG activation as assessed with quantification of Nos2, Ptgs2, 
Il1rn and Socs3 mRNA by RT-qPCR in primary MG exposed to XAV939 (1μM) or DMSO for 4 hours. 
mRNA levels are presented as a fold change relative to DMSO group, mean±SEM, Student’s t-test: * 
p<0.05, ** p<0.01. In (f) a reductions of pro-inflammatory MG activation by gene silencing using 
siRNA for Axin2 (30μM), a β-catenin inhibitor, or scrambled control (Ctrl) siRNA transfected into MG 
for 48 hours prior to 4 hours of IL-1β exposure, see also Supp Figure 3h. siRNA for Axin2 reduces 
IL-1β-induced Nos2, Ptgs2, Il1rn and Socs3 mRNA. Data are presented as a fold change relative to 
negative siRNA group, mean±SEM, one-way ANOVA with post hoc Newman-Keuls’s test: effects of 
IL-1β on gene expression are shown with + p<0.05, ++ p<0.01, +++p<0.001; effects of Axin2 siRNA 
to alter the IL-1β effects are shown with * p<0.05, ** p<0.01, ***p<0.001. In (g) Inhibition of GSK3β, a 
β-catenin inhibitor, by CT99021 (1μM) treatment 1 hour prior to 4 hours of IL-1β exposure reduces 
IL-1β-induced Nos2, Ptgs2, Il1rn and Socs3 mRNA overexpression. mRNA levels are quantified by 
qRT-PCR and presented as a fold change relative to control/DMSO group, (mean±SEM, One-way 
ANOVA with post hoc Newman-Keuls’s test: + p<0.05, ++ p<0.01, +++p<0.001 indicate a statistically 
significant difference between PBS+DMSO and IL-1β+DMSO; * p<0.05, ** p<0.01, ***p<0.001. In (h) 
effects of modulating Wnt with XAV939, Axin2 siRNA and CT99021 on phosphorylation of β-catenin 
(PSer45 β-catenin/β-catenin ratio) were quantified by ELISA in MG. XAV939 (1μM) inhibits β-catenin 
while CT99021 (1μM) or siRNA against Axin2 (30μM) activate it when you compare to their 
respective vehicle (DMSO or negative control siRNA). Data are expressed as the mean±SEM (* 
p<0.05 in a Mann-Whitney test). For all bar graphs the n for each data point is indicated on or above 
the bar. 
 
Figure 4. Wnt/β-catenin pathway regulates MG/Mφ activation and hypomyelination in vivo. Wnt 
signalling was modulated in vivo with pharmacological techniques in zebrafish (a-c) and mice (d) and 
using gene knockout in mice (e-g). In (a) LPS microinjection (5ng/injection) into the zebrafish 
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hindbrain at 72 hpf in pu1::Gal4-UAS::TagRFP morpholinos followed by analysis at 120 hpf. In (b) 
quantification of RFP labelled MG and in (c) representative images of RFP MG in these zebrafish 
brains after LPS injection in the presence or not in their growth solution of modulators of Wnt/β-
catenin signalling, LiCl (80mM), XAV939 (5µM), CT99021 (3µM). Agonists of Wnt (LiCl, CT99021) 
prevented LPS driven MG immunoreactivity and further antagonizing Wnt (XAV939) enhanced this 
inflammatory reactivity. Data are mean±SEM, One-way ANOVA with post hoc Newman-Keuls’s test: 
** p<0.01, ***p<0.001. Scale bar: 40µm. In (d) analysis of CD11B+ cells isolated from P1 mice 
injected i.c.v. with XAV939 (0.5 nmol) alone demonstrating increased MG/Mφ activation. 
Quantification of Nos2, Ptgs2, Tnfα, Il1rn, Socs3 and Il4ra mRNA by RT-qPCR. mRNA levels are 
presented as a fold change relative to PBS/DMSO i.c.v. injected mice. Data expressed as the 
mean±SEM, Student’s t-test: * p<0.05, ** p<0.01 and ***p<0.001. In (e-g) β-catenin deficit in MG 
driven by β-cateninflox/+/LysMCre/+ (β-cateninΔ/+) mice induces hypomyelination. In (e) quantification of 
Mbp mRNA by RT-qPCR at P10 in the anterior brain of β-cateninΔ/+ mice. mRNA levels are 
presented as a fold change relative to WT mice, mean±SEM, Mann–Whitney test: * p<0.05. In (f) the 
β-catenin deficit in β-cateninΔ/+ mice itself induces a decrease of myelin-binding protein MBP 
immunoreactivity (MBP-IR) in the corpus callosum and cingulum at P30 relative to Ctrl (β-
cateninΔ/+/C57Bla6) mice. Results are expressed by grey density, mean±SEM, Mann–Whitney test: * 
p<0.05. In (g) representative images of MBP-IR in the corpus callosum and cingulum at P30 in Ctrl 
and β-cateninΔ/+. Scale bar: 60µm. For all bar graphs the n for each data point is indicated on or 
above the bar. 
 
Figure 5: In human MG activation leads to Wnt/β-catenin down-regulation and genetic 
variation in the Wnt pathway associates with preterm infant white matter phenotype 
In (a) human primary MG exposed to PBS or LPS showing immunoreactive changes with IBA1 plus 
DAPI, scale bar = 50μm, and (b) mRNA expression for COX2 (PTGS2) verifying MG activation by 
LPS and (c) the associated decrease in the expression of the gene for β-catenin (CTNNB1), t-test, 
**p<0.01, ***p<0.0001. In (d) a schematic of the analysis for any association between SNPs in the 
WNT pathway and the preterm infant white matter phenotype. Common genetic variation in the WNT 
gene-set was enriched for variants associated with tractography features when compared to random 
matched gene-sets, competitive test, p=0.037, 1000 permutations, (e blue inset) and is also 
associated with white matter probabilistic tractography in preterm infants, compared with the null 
background, self-contained test, p=0.064, 1000 permutations (e blue inset, e). In (f) are the 
functional descriptions of the ten genes within the WNT gene-set containing SNPs that were most 
significantly associated with the tractography phenotype. In (g) the relationships between these ten 
genes significantly associated with the tractography phenotype is reconstructed in a high confidence 
interaction network specific to the human brain, retrieved from known tissue-specific expression and 
regulatory data (Greene et al 2015). In (h) is the predicted consequences of all of the SNPs found in 
the top 10 ranked WNT genes shown in (f), a total of 42 SNPs.  
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Figure 6. Nanocarrier delivery of a Wnt/β-catenin pathway activator L803mts regulates MG/Mφ 
activation, and prevents hypomyelination and memory impairment in our encephalopathy of 
prematurity model. In (a) representative images of the in vivo uptake of 3DNA by IBA1+ cells in the 
subventricular white matter 4 hours after i.c.v. administration of 3DNA SCR Cy3 (vehicle) or 3DNA 
L803mts Cy3 (200ng), scale bar: 40µm. See also Supp Figure 4a,b and Supp Figure 5. In (b) 
effects of i.c.v. injection of 3DNA L803mts Cy3 to reduce the IL-1β-induced MG/Mφ activation as 
evaluated by qRT-PCR quantification of Nos2, Ptgs2, Tnfα, Il1rn, Socs3 and Il4ra mRNA in CD11B+ 
MG/Mφ cells. mRNA levels are presented as a fold change relative to 3DNA SCR Cy3/PBS group (n 
for each data point is indicated on the bar, mean±SEM, One-way ANOVA with post hoc Newman-
Keuls’s test: ++ p<0.01, +++p<0.001 indicate a statistically significant difference between the PBS 
and the IL-1β  groups also exposed to 3DNA SCR Cy3. For the effects of Wnt modulator delivery, * 
p<0.05, ** p<0.01. In (c) representative images of in vivo uptake of 3DNA by IBA1+ cells in 
subventricular white matter at P5 after i.p. injections of 3DNA L803mts Cy3 or 3DNA SCR Cy3 
(500ng/injection) concurrently with PBS or IL-1β i.p. injections from P1-P5. Scale bar: 40µm. In (d) 
effect of i.p. injections of 3DNA L803mts Cy3 to prevent the IL-1β-induced loss of Mbp mRNA levels 
as quantified by qRT-PCR in anterior brain of mice at P10. mRNA levels are presented as a fold 
change relative to 3DNA SCR Cy3/PBS group (n for each data point is indicated on the bar, mean± 
SEM, one way-ANOVA with Bonferroni’s post hoc test: ***p<0.001, * p<0.05). See also Supp Figure 
4c,d. To show that systemically delivered 3DNA L803mts Cy3 led to functional improvements in our 
model together with the structural changes we performed Barnes maze testing to evaluate spatial 
learning (e) and memory (f,g) in 3-month-old mice after i.p. injections of PBS or IL-1β from P1-P5 
concurrently with treatment with 3DNA SCR Cy3 or 3DNA L803mts Cy3. See also Supp Figure 6. In 
(e) learning was evaluated by recording the number of errors and distance travelled to reach the 
target (escape box) over 5 consecutive days. In (f) we show that 3DNA SCR Cy3 treatment 
ameliorated the negative effects of IL-1β-exposure on memory retention present in the 0-30 second 
trial period on day 5 of the test (probe trial) as measured by recording of the distance travelled in the 
target sextant, and in (g) we show that 3DNA SCR Cy3 treatment ameliorated the negative effects of 
IL-1β-exposure on the long-term memory deficits as measured via the distance travelled to reach the 
target on the 15th day after the start of testing. For probe trial comparisons, a univariate t test was 
performed to compare the % time spent in the target sextant to the theoretical value 16.67%, i.e. 
when the mouse spent equal time within each sextant, * p<0.05. For long-term memory analysis, a 
one-way ANOVA with Bonferroni post hoc was used ** p<0.01. 
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Supplementary figures 
 
Supplementary Figure 1 related to Figure 2. Expression of phenotype markers by MG/Mφ in 
IL-1β treated mice at P3. (a) Quantification of CD16+, CD68+/iNOS+, CD68+/COX2+, 
CD68+/ARG1+ and MR (CD206)+ cells at P3 from PBS and IL-1β treated mice. Data are expressed 
as the number of positive cells per field and the number of animals is shown on the graph (Mann-
Whitney test: mean±SEM; * p<0.05 and **p<0.01). Representative images at P3 in the corpus 
callosum of the effect of IL-1β on the number of (b) CD68+/iNOS+ and CD68+/ARG1+ cells (c) 
CD68+/COX2+ and (d) CD16+ and MR+ cells. Scale bar: 50µm 
 
Supplementary Figure 2 related to Figure 3 and Supp Table 1. Properties of the networks 
formed from the transcriptomic analysis of MG and oligodendrocytes following exposure to 
IL-1β. In (a) the structural properties of the transcriptomic network from the microarray analysis 
performed on CD11B+ and O4+ cell fractions isolated by MACS. Reconstructed gene networks by 
cell type and condition, local FDR <1% (OG: oligodendrocytes; MG MG/Mφ; PBS: control). (b) Visual 
representation of the output of transcriptomic analysis of MG and oligodendrocytes following 
exposure to IL-1β. Under control conditions (PBS) the OG co-expression network appears less 
dense, structured with interconnected clusters (34 connected components) where most genes are 
not direct neighbours of one another (characteristic path length 5.5). With exposure to IL-1β there is 
a noticeable change in the OG network structure, so that there are many more genes being co-
expressed (an increase from 571 nodes, 1229 edges in PBS to 1583 nodes, 6457 edges in IL-1β) 
and they are more highly interconnected (characteristic path length 2.9). The control (PBS) MG co-
expression network is also relatively clustered and less dense, and on exposure to IL-1β there is a 
dramatic increase in co-expression (786 nodes, 1810 edges in PBS to 3113 nodes and 48104 edges 
in IL-1β). This demonstrates that at rest MG are more transcriptionally active than OG, and both cell-
types respond strikingly to IL-1β exposure with a global activation of gene expression that is 
particularly pronounced for MG.  
 
Supplementary Figure 3 related to Figure 4. Validation in primary MG of an inverse 
relationship between pro-inflammatory status and the Wnt/β-catenin pathway. In (a) MG 
phenotype induced by IL-1β was assessed via pro-inflammatory markers (Cd32, Cd86, Nos2 and 
Ptgs2), anti-inflammatory markers (Arg1, Cd206, Igf1 and Lgals3) and immuno-regulator markers 
(Il1rn, Il4ra, Socs3 and Sphk1) by RT-qPCR after 4 hours of IL-1β stimulation. mRNA levels are 
presented as a fold change relative to PBS exposed MG. Data are expressed as mean±SEM, in 
brackets are for the n PBS and IL-1β groups (Student’s t-test: * p<0.05, ** p<0.01 and ***P<0.001). 
(b) MG phenotype induced after 4 hours of exposure to IL-1β in primary MG as assessed with 
immunoreactivity (IR) for COX2 (pro-inflammatory) ARG1 (anti-inflammatory) and IL1RA (immuno-
regulator). Scale bar: 50µm. (c) Canonical Wnt pathway expression as altered by IL-1β exposure in 
primary MG as assessed by RT-qPCR for Ctnnb1, Tcf1, Lef1 and Wnt receptors Frizzled (Fzd) 3,4,6 
mRNA after 4 hours of stimulation. mRNA levels are presented as a fold change relative to control 
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(PBS treated) MG. Data are expressed as the mean±SEM and n are indicated in the columns 
(Student’s t-test: * p<0.05, ** p<0.01 and *** p<0.001). (d) IL-1β induces down-regulation of β-catenin 
immunoreactivity in primary MG after 4 hours of stimulation. Scale bar: 50µm. (e) IL-1β induces 
down-regulation of total β-catenin without any modification of the PSer45 β-catenin/β-catenin ratio as 
assessed via ELISA (normalized to PBS control) in primary MG after 4 hours of stimulation. Data are 
expressed as the mean±SEM (Student t-test: * p<0.05, ** p<0.01 and *** p<0.001). (f) Expression of 
members of the canonical Wnt pathway in primary MG activated by IL-4 (20ng/ml) as assessed by 
RT-qPCR for Ctnnb1, Tcf1 and Lef1 after 4 hours of stimulation. mRNA levels are presented as a 
fold change relative to control (PBS treated) MG. Data are expressed as the mean±SEM, (Student’s 
t-test: * p<0.05, ** p<0.01 and *** p<0.001). (g) IL-4 induces down-regulation of Pser45 β-catenin/β-
catenin ratio without any modification of total β-catenin in primary MG as assessed with ELISA after 4 
hours of stimulation. Data are expressed as the mean±SEM (Student’s t-test: * p<0.05, ** p<0.01 and 
*** p<0.001). 
 
Supplementary Figure 4. Non-canonical Wnt pathway blockade has no effect on the activation 
of primary MG stimulated by IL-1β. Inhibition of Protein Kinase C by Chelerythrine has no effect on 
MG activation. Quantification of Nos2, Ptgs2, Il1rn and Socs3 mRNA by RT-qPCR in control (PBS) 
and IL-1β treated primary MG with Chelerythrine (1 or 3μM) or DMSO. mRNA levels are presented 
as a fold change relative to control/DMSO group. (mean±SEM; # p<0.05, ## p<0.01, showed 
significant difference between PBS/DMSO and IL-1β/DMSO groups. Kruskal-Wallis test with Dunns 
post-hoc test). Data are from 3 independently replicated experiments.  
 
Supplementary Figure 5 related to Figure 6. Cell and organ specific analysis of the uptake  by 
MG of 3DNA Cy3 labelled nanoparticles. (a) 3DNA uptake by IBA-1+ cells in mixed primary 
cultures of astrocytes, OPCs and MG after incubation with 3DNA Cy3 (200ng/ml) for 24 hours. Scale 
bar: 40µm. (b) 3DNA uptake by a primary MG following incubation with 3DNA L803mts Cy3 
(200ng/ml) for 5 hours. Scale bar: 10µm. Representative images of the undetectable uptake of 3DNA 
by the (c) spleen and (d) the liver. Scale bar: 100µm 
 
Supplementary Figure 6. Nanocarrier-mediated delivery of a Wnt/β-catenin pathway activator 
L803mts regulates MG/Mφ activation in primary MG. In (a) representative images of the in vitro 
uptake of 3DNA by primary MG 4 hours after 3DNA L803mts Cy3 exposure. In (b) effects of 3DNA 
L803mts Cy3 exposure to reduce the IL-1β-induced MG/Mφ activation as evaluated by qRT-PCR 
quantification of Nos2, Ptgs2, Tnfα, Il1rn, Socs3 and Il4ra mRNA. mRNA levels are presented as a 
fold change relative to 3DNA SCR Cy3/PBS group (n for each data point is indicated on the bar, 
mean±SEM, One-way ANOVA with post hoc Newman-Keuls’s test: ++ p<0.01, +++p<0.001 indicate 
a statistically significant difference between the PBS and the IL-1β  groups also exposed to 3DNA 
SCR Cy3. For the effects of Wnt modulator delivery, * p<0.05, ** p<0.01.  
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Supplementary Figure 7. Nanocarrier-mediated delivery of a Wnt/β-catenin pathway activator 
L803mts has no effect on indices of basal behaviour in our encephalopathy of prematurity 
model. In (a) Actimetry data including horizontal locomotion and rearing over a 24 hour period, 
mean±SEM. In (b) data on distance travelled and time spent inactive in the Open Field test, 
mean±SEM.  
 
 
Supplementary tables 
 
Supp Table 1.  Genes found within the co-expression networks for each of the four GGM outputs. 
See also, Supp Figure 1.   
 
Supp Table 2.  Biological pathway analysis using the Broad Institute MsigDB database for each of 
the four conditions. Of note for MG exposed to IL1B Wnt signalling is highly significantly enriched.   
 
Supp Table 3.  GSEA including genes down-reguated in the array analysis, showing a 
predominance of   Wnt enrichment in the down-regulated genes. 
 
Supp Table 4. Analysis of the 10 highly ranked genes showing statistical outputs in full for an 
association with the white matter connectivity phenotype. 
 
Supp Table 5.  Genes creating a coherent interaction network built around the 10 WNT pathway 
genes with SNPs highly associated with the preterm white matter connectivity phenotype. 
 
Supp Table 6. Details for each of the 42 SNPs for analysis from the 10 genes most highly 
associated with the preterm white matter phenotype 
 
Supp Table 7. Consequences predicted for the 42 SNPs found in the 10 genes of high relevance to 
the preterm white matter connectivity phenotype. Summary of effects found in Figure 5h. 
 
Supp Table 8. List of primer sequences 
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